36,245 Shares in Senseonics Holdings Inc (SENS) Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp purchased a new position in Senseonics Holdings Inc (NYSEAMERICAN:SENS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 36,245 shares of the company’s stock, valued at approximately $116,000.
Several other institutional investors have also modified their holdings of SENS. Goldman Sachs Group Inc. bought a new position in shares of Senseonics in the 2nd quarter worth about $276,000. Raymond James Financial Services Advisors Inc. grew its position in Senseonics by 221.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 263,562 shares of the company’s stock valued at $474,000 after purchasing an additional 181,562 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Senseonics during the 2nd quarter valued at about $155,000. Institutional investors own 30.66% of the company’s stock.
Separately, Canaccord Genuity reissued a “buy” rating on shares of Senseonics in a research report on Thursday, September 28th.
Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings data on Tuesday, October 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $2.10 million for the quarter, compared to the consensus estimate of $1.51 million. Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company’s revenue was up 425.0% on a year-over-year basis. sell-side analysts forecast that Senseonics Holdings Inc will post -0.54 earnings per share for the current year.
In other Senseonics news, major shareholder Peter J. Barris sold 139,645 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $2.63, for a total transaction of $367,266.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 34.10% of the company’s stock.
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings Inc (NYSEAMERICAN:SENS).
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.